Objective

2

To investigate the efficacy of Shengxuebao Mixture in supporting the treatment of bone marrow suppression following autologous hematopoietic stem cell transplantation （AHSCT） in patients with hematologic malignancies.

Methods

2

A retrospective analysis was conducted on 102 patients with hematologic malignancies who underwent AHSCT. Patients were divided into an observation group （

n

=52） and a control group （

n

=50） based on whether they received Shengxuebao Mixture. The control group received cytokine therapy alone， while the observation group received Shengxuebao Mixture in addition to cytokine therapy. Both groups continued treatment until hematopoietic stem cell engraftment. Hematologic parameters， including white blood cell count， reticulocyte count， platelet count， hemoglobin， and erythropoietin levels， were compared between the two groups， along with the engraftment times for granulocyte and megakaryocyte lineages and the incidence of adverse reactions.

Results

2

①Post-treatment comparisons between groups revealed that the observation group had significantly higher reticulocyte count， hemoglobin， and erythropoietin levels than the control group （

P

<

0.05）. ②Granulocytic and megakaryocytic engraftment times were shorter in the observation group than in the control group （

P

<

0.05）. ③There was no statistically significant difference in the incidence of adverse reactions between the two groups （

P

>

0.05）.

Conclusion

2

Compared to cytokine therapy alone， adding Shengxuebao Mixture can better promote bone marrow function recovery after AHSCT in patients with hematologic malignancies， thus alleviating bone marrow suppression.